Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.

Baertsch, Marc-Andrea; Hundemer, Michael; Hillengass, Jens; Goldschmidt, Hartmut; Raab, Marc S

Baertsch, Marc-Andrea; Hundemer, Michael; Hillengass, Jens; Goldschmidt, Hartmut; Raab, Marc S.

Affiliation

Baertsch MA; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Hundemer M; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Hillengass J; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Goldschmidt H; Department of Radiology, German Cancer Research Center, Heidelberg, Germany.
Raab MS; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

Hematol Oncol ; 36(1): 258-261, 2018 Feb.

Article in En | MEDLINE | ID: mdl-28840598

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Multiple Myeloma/drug therapy; Thalidomide/analogs & derivatives; Aged; Angiogenesis Inhibitors/pharmacology; Antibodies, Monoclonal; Humans; Multiple Myeloma/mortality; Survival Analysis; Thalidomide/pharmacology; Thalidomide/therapeutic use

Key words

daratumumab; monoclonal antibodies; pomalidomide; refractory multiple myeloma; rituximab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Angiogenesis Inhibitors / Multiple Myeloma Limits: Aged / Humans Language: En Journal: Hematol Oncol Year: 2018 Type: Article Affiliation country: Germany

Fulltext

XML

PubMed Links

Search on Google